Home » Stocks » SMMT

Summit Therapeutics PLC (SMMT)

Stock Price: $6.77 USD -0.20 (-2.87%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Pre-market: $6.90 +0.13 (1.92%) Mar 1, 8:25 AM
Market Cap 559.03M
Revenue (ttm) 22.09M
Net Income (ttm) -50.29M
Shares Out 335.89M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $6.77
Previous Close $6.97
Change ($) -0.20
Change (%) -2.87%
Day's Open 6.98
Day's Range 6.51 - 7.00
Day's Volume 138,740
52-Week Range 3.14 - 12.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 months ago

Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

Summit Therapeutics Inc. (‘Summit,' the ‘Company,' or the ‘Group')

GlobeNewsWire - 3 months ago

Summit Therapeutics Inc. (‘Summit', the ‘Company' or the ‘Group')

GlobeNewsWire - 3 months ago

Summit Therapeutics Inc. (“Summit” or the “Company”)

GlobeNewsWire - 4 months ago

Summit Therapeutics Inc.

GlobeNewsWire - 5 months ago

Summit Therapeutics Inc. (‘Summit’, the ‘Company’ or the ‘Group’)

GlobeNewsWire - 5 months ago

Summit Therapeutics Inc.

GlobeNewsWire - 5 months ago

Summit Therapeutics plc

GlobeNewsWire - 6 months ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 7 months ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 7 months ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 8 months ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

Zacks Investment Research - 8 months ago

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.

GlobeNewsWire - 8 months ago

Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’)

Zacks Investment Research - 8 months ago

Is (SMMT) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 9 months ago

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.

Zacks Investment Research - 9 months ago

Is (SMMT) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 9 months ago

Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.11, moving +0.33% from the previous trading session.

Zacks Investment Research - 10 months ago

Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.68, moving +0.55% from the previous trading session.

Zacks Investment Research - 10 months ago

Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zacks Investment Research - 10 months ago

Does Summit Therapeutics PLC (SMMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 10 months ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

Zacks Investment Research - 10 months ago

Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to g...

Other stocks mentioned: DHT, FRO, KALA, SMED
Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for April 7th

Other stocks mentioned: EURN, LIVX, RDHL
Zacks Investment Research - 11 months ago

Top Ranked Momentum Stocks to Buy for March 26th

Other stocks mentioned: GO, NPTN
Zacks Investment Research - 11 months ago

Top Ranked Momentum Stocks to Buy for March 25th

Other stocks mentioned: VIPS, VXRT
GlobeNewsWire - 1 year ago

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

TR-1: S tandard form for notification of major holdings

GlobeNewsWire - 1 year ago

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ’Company’)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICT...

Zacks Investment Research - 1 year ago

Summit Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Summit Therapeutics.

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

GlobeNewsWire - 1 year ago

Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’)

Seeking Alpha - 1 year ago

October's R&D day should include new Phase 2 data for the company's lead candidate ridinilazole.

About SMMT

Summit Therapeutics, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; ... [Read more...]

Industry
Biotechnology
Founded
2003
CEO
Robert W. Duggan
Employees
70
Stock Exchange
NASDAQ
Ticker Symbol
SMMT
Full Company Profile

Financial Performance

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for SMMT is 4.50, which is a decrease of -33.53% from the latest price.

Price Target
$4.50
(-33.53% downside)